NCT05791565View on ClinicalTrials.gov

Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

May 21, 2023

Study Completion Date

May 21, 2023

Conditions

Asthma

Interventions

DRUG

Salbutamol HFA-152a

Salbutamol HFA-152a will be administered.

DRUG

Salbutamol HFA-134a

Salbutamol HFA-134a will be administered.

Trial Locations (1)

9728 NZ

GSK Investigational Site, Groningen

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT05791565 - Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants | Biotech Hunter | Biotech Hunter